Favorable Effect of Immunomodulator Therapy on Bone Mineral Density in Multiple Sclerosis

Overview

Journal Ir J Med Sci

Specialty General Medicine

Date 2008 Nov 13

PMID 19002746

Citations 12

Authors

M Shuhaibar

M J McKenna

M Au-Yeong

J M T Redmond

Affiliations

Soon will be listed here.

Abstract

Background: Osteoporosis is a complication of multiple sclerosis (MS), especially if corticosteroid therapy is given. Little is known about the effect on bone of immunomodulatory therapy (IMT) for MS.

Aim: We sought to evaluate bone mass in patients with MS on IMT.

Methods: We measured bone mineral density (BMD) by dual energy X-ray absorptiometry (DXA) in 37 patients with MS who received IMT. Different IMTs were administered: interferon beta-1a in 70%, interferon beta-1b in 27% and Glatiramer in 3%. High-dose pulse corticosteroid therapy (intravenous methylprednisolone 500 mg) was given to 81% ranging from 1 to 17 courses.

Results: Both mean BMD Z-score at spine of 0.53 (CI, 0.15-0.92; P = 0.0084) and mean BMD Z-score at femur of 0.72 (CI, 0.42-1.01; P < 0.0001) were significantly greater than zero.

Conclusions: IMT may have a favorable effect on bone in patients with MS even in the presence of pulse steroid therapy.

Citing Articles

Medication and bone health in multiple sclerosis: A systematic review and meta-analysis.

Cahyadi M, Mesinovic J, Chim S, Ebeling P, Zengin A, Grech L J Manag Care Spec Pharm. 2023; 29(12):1331-1353.

PMID: 38058136 PMC: 10776270. DOI: 10.18553/jmcp.2023.29.12.1331.

Risk Factors, Epidemiology and Treatment Strategies for Metabolic Bone Disease in Patients with Neurological Disease.

Binks S, Dobson R Curr Osteoporos Rep. 2016; 14(5):199-210.

PMID: 27525980 DOI: 10.1007/s11914-016-0320-5.

Signaling pathway STAT1 is strongly activated by IFN-β in the pathogenesis of osteoporosis.

Seeliger C, Schyschka L, Kronbach Z, Wottge A, van Griensven M, Wildemann B Eur J Med Res. 2015; 20:1.

PMID: 25563300 PMC: 4300729. DOI: 10.1186/s40001-014-0074-4.

Osteoporosis and multiple sclerosis: risk factors, pathophysiology, and therapeutic interventions.

Gupta S, Ahsan I, Mahfooz N, Abdelhamid N, Ramanathan M, Weinstock-Guttman B CNS Drugs. 2014; 28(8):731-42.

PMID: 24871932 DOI: 10.1007/s40263-014-0173-3.

Assessment of bone densitometry in Iranian patients with multiple sclerosis: A case-control study.

Moghaddasi M, Aghaei M Iran J Neurol. 2013; 12(1):9-14.

PMID: 24250890 PMC: 3829271.

References

Formica C, Cosman F, Nieves J, Herbert J, Lindsay R . Reduced bone mass and fat-free mass in women with multiple sclerosis: effects of ambulatory status and glucocorticoid Use. Calcif Tissue Int. 1997; 61(2):129-33. DOI: 10.1007/s002239900309. View

Then Bergh F, Kumpfel T, Schumann E, Held U, Schwan M, Blazevic M . Monthly intravenous methylprednisolone in relapsing-remitting multiple sclerosis - reduction of enhancing lesions, T2 lesion volume and plasma prolactin concentrations. BMC Neurol. 2006; 6:19. PMC: 1501038. DOI: 10.1186/1471-2377-6-19. View

Takayanagi H, Kim S, Matsuo K, Suzuki H, Suzuki T, Sato K . RANKL maintains bone homeostasis through c-Fos-dependent induction of interferon-beta. Nature. 2002; 416(6882):744-9. DOI: 10.1038/416744a. View

Cosman F, Nieves J, Komar L, Ferrer G, Herbert J, Formica C . Fracture history and bone loss in patients with MS. Neurology. 1998; 51(4):1161-5. DOI: 10.1212/wnl.51.4.1161. View

Stuart W, Cohan S, Richert J, Achiron A . Selecting a disease-modifying agent as platform therapy in the long-term management of multiple sclerosis. Neurology. 2004; 63(11 Suppl 5):S19-27. DOI: 10.1212/wnl.63.11_suppl_5.s19. View

Zivadinov R, Zorzon M, De Masi R, Nasuelli D, Cazzato G . Effect of intravenous methylprednisolone on the number, size and confluence of plaques in relapsing-remitting multiple sclerosis. J Neurol Sci. 2007; 267(1-2):28-35. DOI: 10.1016/j.jns.2007.09.025. View

Kanis J, Johnell O, Oden A, Johansson H, McCloskey E . FRAX and the assessment of fracture probability in men and women from the UK. Osteoporos Int. 2008; 19(4):385-97. PMC: 2267485. DOI: 10.1007/s00198-007-0543-5. View

Baim S, Binkley N, Bilezikian J, Kendler D, Hans D, Lewiecki E . Official Positions of the International Society for Clinical Densitometry and executive summary of the 2007 ISCD Position Development Conference. J Clin Densitom. 2008; 11(1):75-91. DOI: 10.1016/j.jocd.2007.12.007. View

De Stefano N, Filippi M, Hawkins C . Short-term combination of glatiramer acetate with i.v. steroid treatment preceding treatment with GA alone assessed by MRI-disease activity in patients with relapsing-remitting multiple sclerosis. J Neurol Sci. 2007; 266(1-2):44-50. DOI: 10.1016/j.jns.2007.08.036. View

10.

Peterson E, Cho C, von Koch L, Finlayson M . Injurious falls among middle aged and older adults with multiple sclerosis. Arch Phys Med Rehabil. 2008; 89(6):1031-7. DOI: 10.1016/j.apmr.2007.10.043. View

11.

Weinstock-Guttman B, Hong J, Santos R, Tamano-Blanco M, Badgett D, Patrick K . Interferon-beta modulates bone-associated cytokines and osteoclast precursor activity in multiple sclerosis patients. Mult Scler. 2006; 12(5):541-50. DOI: 10.1177/1352458506070605. View

12.

McKenna M, van der Kamp S, Au-Yeong M, FitzGerald O . Improving standards of DXA. Ir Med J. 2008; 101(4):101-2. View

13.

Looker A, Wahner H, Dunn W, Calvo M, Harris T, Heyse S . Proximal femur bone mineral levels of US adults. Osteoporos Int. 1995; 5(5):389-409. DOI: 10.1007/BF01622262. View

14.

Castrillon J, Cano-Del Pozo M, Sanz-Izquierdo S, Velayos-Jimenez J, Dib-Wobakin W . [Bone mineral density in patients with multiple sclerosis: the effects of interferon]. Rev Neurol. 2003; 36(10):901-3. View

15.

Schwid S, Goodman A, Puzas J, McDermott M, Mattson D . Sporadic corticosteroid pulses and osteoporosis in multiple sclerosis. Arch Neurol. 1996; 53(8):753-7. DOI: 10.1001/archneur.1996.00550080071014. View